Clinical, molecular, and immunological responses to pembrolizumab treatment of synchronous melanoma and acute myeloid leukemia

• Anne Sophie Kubasch,
• Rebekka Wehner,
• Serena Bazzurri,
• Antje Tunger,
• Sebastian Stasik,
• Marlene Garzarolli,
• Jörn Meinel,
• Gustavo Baretton,
• Friedegund Meier,
• Christian Thiede,
• Marc Schmitz,
• Uwe Platzbecker

Affiliations

Anne Sophie Kubasch

Center for Rare Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;

Rebekka Wehner

Institute of Immunology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; German Cancer Consortium, Dresden, Germany;; German Cancer Research Center, Heidelberg, Germany;

Serena Bazzurri

Department of Oncology, Santo Stefano Hospital, Prato, Italy;

Antje Tunger

Institute of Immunology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;

Sebastian Stasik

Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;

Marlene Garzarolli

Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Jörn Meinel

Institute of Pathology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Gustavo Baretton

National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; German Cancer Consortium, Dresden, Germany;; German Cancer Research Center, Heidelberg, Germany;; Institute of Pathology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Friedegund Meier

National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; German Cancer Consortium, Dresden, Germany;; German Cancer Research Center, Heidelberg, Germany;; Department of Dermatology, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany

Christian Thiede

Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; German Cancer Consortium, Dresden, Germany;; German Cancer Research Center, Heidelberg, Germany;

Marc Schmitz

Institute of Immunology, Medical Faculty Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; German Cancer Consortium, Dresden, Germany;; German Cancer Research Center, Heidelberg, Germany;

Uwe Platzbecker

Center for Rare Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; National Center for Tumor Diseases, University Hospital Carl Gustav Carus, Technische Universität Dresden, Dresden, Germany;; German Cancer Consortium, Dresden, Germany;; German Cancer Research Center, Heidelberg, Germany;; Uwe Platzbecker, Medical Clinic and Policlinic I, University Hospital Carl Gustav Carus, TU Dresden, Fetscherstr 74, 01307 Dresden, Germany;